Our Vision is to build an international, high-growth oncology business, focused on new and improved anti-cancer drugs.
Our candidate products are innovative new chemical medicines with the potential to achieve clinical breakthroughs in cancer treatment to deliver real benefits to patients.
We intend to create substantial value for shareholders as we build a successful and profitable speciality oncology business.
Clavis Pharma intends to leverage its Lipid Vector Technology to develop of a strong pipeline of proprietary new and improved cancer drugs.
The Company aims to commercialise its products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities.
Clavis Pharma's revenues therefore are primarily expected to come from partnering agreements in the form of up-front and milestone payments, product sales and royalties on product sales.